AR040839A1 - Formas cristalinas de [4-carbamoil-1-(3-fluorbencil)-2, 7-dihidroxi-7-metil-octil]-amida del acido quinoxalina-2- carboxilico - Google Patents
Formas cristalinas de [4-carbamoil-1-(3-fluorbencil)-2, 7-dihidroxi-7-metil-octil]-amida del acido quinoxalina-2- carboxilicoInfo
- Publication number
- AR040839A1 AR040839A1 AR20030102881A ARP030102881A AR040839A1 AR 040839 A1 AR040839 A1 AR 040839A1 AR 20030102881 A AR20030102881 A AR 20030102881A AR P030102881 A ARP030102881 A AR P030102881A AR 040839 A1 AR040839 A1 AR 040839A1
- Authority
- AR
- Argentina
- Prior art keywords
- quinoxaline
- amide
- methyl
- fluorbencil
- dihidroxi
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 229950004492 octil Drugs 0.000 title 1
- RALCLUSHFOIHOL-UHFFFAOYSA-N 5-amino-6-(3-fluorophenyl)-4-hydroxy-2-(3-hydroxy-3-methylbutyl)hexanamide Chemical compound CC(C)(O)CCC(C(N)=O)CC(O)C(N)CC1=CC=CC(F)=C1 RALCLUSHFOIHOL-UHFFFAOYSA-N 0.000 abstract 1
- 102000004500 CCR1 Receptors Human genes 0.000 abstract 1
- 108010017319 CCR1 Receptors Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- UPUZGXILYFKSGE-UHFFFAOYSA-N quinoxaline-2-carboxylic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CN=C21 UPUZGXILYFKSGE-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se refiere a formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amida del ácido quinoxalina -2-carboxílico, útiles en el tratamiento o prevención de un trastorno o afección por medio de la antagonización del receptor CCR1, y a sus métodos de preparación y uso.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40321602P | 2002-08-12 | 2002-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040839A1 true AR040839A1 (es) | 2005-04-20 |
Family
ID=31715961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20030102881A AR040839A1 (es) | 2002-08-12 | 2003-08-08 | Formas cristalinas de [4-carbamoil-1-(3-fluorbencil)-2, 7-dihidroxi-7-metil-octil]-amida del acido quinoxalina-2- carboxilico |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20040072834A1 (es) |
| EP (1) | EP1539715A1 (es) |
| JP (1) | JP2005538130A (es) |
| AP (1) | AP2005003226A0 (es) |
| AR (1) | AR040839A1 (es) |
| AU (1) | AU2003250450A1 (es) |
| BR (1) | BR0313378A (es) |
| CA (1) | CA2494776A1 (es) |
| EC (1) | ECSP055588A (es) |
| GT (1) | GT200300169A (es) |
| IL (1) | IL166548A0 (es) |
| IS (1) | IS7674A (es) |
| MX (1) | MXPA05001781A (es) |
| NO (1) | NO20050540L (es) |
| OA (1) | OA12894A (es) |
| PA (1) | PA8580401A1 (es) |
| PE (1) | PE20040866A1 (es) |
| TN (1) | TNSN05035A1 (es) |
| TW (1) | TW200407316A (es) |
| UY (1) | UY27928A1 (es) |
| WO (1) | WO2004014875A1 (es) |
| ZA (1) | ZA200500768B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY33110A (es) | 2009-12-23 | 2011-07-29 | Ironwood Pharmaceuticals Inc | Moduladores de CRTH2 |
| WO2012009134A1 (en) | 2010-07-12 | 2012-01-19 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| WO2012009137A1 (en) | 2010-07-12 | 2012-01-19 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| CN102276539B (zh) * | 2011-06-29 | 2013-08-14 | 赵雪梅 | 一种具有抑菌作用的化合物及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (es) * | 1962-12-19 | |||
| US3492397A (en) * | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) * | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) * | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) * | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| US6403587B1 (en) * | 1997-02-26 | 2002-06-11 | Pfizer Inc. | Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1-α binding to its CCR 1 receptor |
| UA57824C2 (uk) * | 1998-02-05 | 2003-07-15 | Пфайзер Продактс Інк. | Похідні дигідроксигексанової кислоти, фармацевтична композиція, що їх містить (варіанти), та спосіб лікування (варіанти) |
-
2003
- 2003-07-31 OA OA1200500028A patent/OA12894A/en unknown
- 2003-07-31 AU AU2003250450A patent/AU2003250450A1/en not_active Abandoned
- 2003-07-31 WO PCT/IB2003/003464 patent/WO2004014875A1/en not_active Application Discontinuation
- 2003-07-31 CA CA002494776A patent/CA2494776A1/en not_active Abandoned
- 2003-07-31 JP JP2004527195A patent/JP2005538130A/ja active Pending
- 2003-07-31 BR BR0313378-8A patent/BR0313378A/pt not_active Application Discontinuation
- 2003-07-31 AP AP2005003226A patent/AP2005003226A0/xx unknown
- 2003-07-31 MX MXPA05001781A patent/MXPA05001781A/es not_active Application Discontinuation
- 2003-07-31 EP EP03784383A patent/EP1539715A1/en not_active Withdrawn
- 2003-08-05 UY UY27928A patent/UY27928A1/es not_active Application Discontinuation
- 2003-08-06 TW TW092121503A patent/TW200407316A/zh unknown
- 2003-08-06 GT GT200300169A patent/GT200300169A/es unknown
- 2003-08-08 AR AR20030102881A patent/AR040839A1/es unknown
- 2003-08-08 PE PE2003000794A patent/PE20040866A1/es not_active Application Discontinuation
- 2003-08-08 US US10/637,475 patent/US20040072834A1/en not_active Abandoned
- 2003-08-12 PA PA20038580401A patent/PA8580401A1/es unknown
-
2005
- 2005-01-26 ZA ZA200500768A patent/ZA200500768B/xx unknown
- 2005-01-27 IL IL16654805A patent/IL166548A0/xx unknown
- 2005-01-27 IS IS7674A patent/IS7674A/is unknown
- 2005-01-31 NO NO20050540A patent/NO20050540L/no unknown
- 2005-02-03 EC EC2005005588A patent/ECSP055588A/es unknown
- 2005-02-11 TN TNP2005000035A patent/TNSN05035A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200500768B (en) | 2006-07-26 |
| IL166548A0 (en) | 2006-01-15 |
| MXPA05001781A (es) | 2005-04-25 |
| JP2005538130A (ja) | 2005-12-15 |
| TNSN05035A1 (fr) | 2007-05-14 |
| OA12894A (en) | 2006-10-13 |
| EP1539715A1 (en) | 2005-06-15 |
| CA2494776A1 (en) | 2004-02-19 |
| US20040072834A1 (en) | 2004-04-15 |
| GT200300169A (es) | 2004-05-12 |
| IS7674A (is) | 2005-01-27 |
| PA8580401A1 (es) | 2004-02-16 |
| UY27928A1 (es) | 2004-03-31 |
| BR0313378A (pt) | 2005-07-12 |
| AU2003250450A1 (en) | 2004-02-25 |
| AP2005003226A0 (en) | 2005-03-31 |
| WO2004014875A1 (en) | 2004-02-19 |
| PE20040866A1 (es) | 2004-11-26 |
| ECSP055588A (es) | 2005-04-18 |
| NO20050540L (no) | 2005-03-10 |
| TW200407316A (en) | 2004-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8579601A1 (es) | Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas | |
| AU2003272285A8 (en) | Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands | |
| ECSP045081A (es) | Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados | |
| DE602004021585D1 (de) | 5,7-DIAMINOPYRAZOLOi4,3-D PYRIMIDINE ZUR VERWENDUNG IN DER BEHANDLUNG VON BLUTHOCHDRUCK | |
| UY28766A1 (es) | Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico | |
| NO20054371L (no) | Somatostatin-dopamin kimaere analoger | |
| WO2005102396A3 (en) | Multimodality nanostructures, methods of fabrication thereof, and methods of use thereof | |
| IS2733B (is) | Afleiður af díoxan-2-alkýlkarbamötum, framleiðsluaðferð þeirra, milliefni notuð við framleiðsluna, og notkun þeirra í meðferð. | |
| CL2013001723A1 (es) | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina; metodos de preparacion; composicion farmaceutica; y el uso en el tratamiento de los trastornos mediados por la cinasa de linfoma anaplasico. | |
| CL2006003736A1 (es) | Compuestos derivados de triazina o pirimidina sustituida, antagonistas del receptor de prokineticina 1, composicion farmaceutica; y uso en el tratamiento de trastornos gastrointestinales. | |
| NO20055741L (no) | Nye kjemiske forbindelser | |
| WO2006066950A3 (de) | Tricyclische aminoalkohole, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer | |
| ATE409188T1 (de) | Naphthyridinverbindungen | |
| EA200701592A1 (ru) | Композиты и способы их получения и использования | |
| DE602004018630D1 (en) | Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten | |
| BR0315644A (pt) | Piperazinil e diazapanil benzamidas e benzotioamidas | |
| MXPA05009014A (es) | Antagonistas del receptor ccr-3. | |
| EA200501924A1 (ru) | Способ лечения тревожного расстройства | |
| CL2008003659A1 (es) | Compuestos derivados de 6-(4-bencilpiperazin-1-il)pirimidin-4-ona, moduladores de la enzima estearoil-coa-desaturasa 1; procedimiento de preparacion; composicin farmaceutica; y uso en el tratamiento y profilaxis de la obesidad. | |
| ECSP055588A (es) | Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amida del ácido quinoxalina-2-carboxilico | |
| IS7910A (is) | Samsett lyf | |
| ECSP044971A (es) | Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson | |
| CY1109803T1 (el) | Φαρμακευτικες συνθεσεις που βασιζονται σε ανταγωνιστες νκ2 για παιδιατρικη χρηση | |
| DOP2003000682A (es) | Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,3-dihidroxi-7-metil-octil]-amida del acido quinoxalina-2-carboxilico | |
| DK1526848T3 (da) | Opiod-receptorantagonister i transdermale systemer med buprenorphin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |